Placebo effects on itch: A meta-analysis of clinical trials of patients with dermatological conditions

Journal of Investigative Dermatology

Volumn 135, Issue 5, 2015, Pages 1234-1243

  Van Laarhoven, Antoinette I M ^a,b   Van Der Sman Mauriks, Ineke M ^a   Donders, A Rogier T ^b   Pronk, Mathilde C ^a   Van De Kerkhof, Peter C M ^b   Evers, Andrea W M ^a,b  

^a LEIDEN UNIVERSITY   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; ANTIPRURITIC AGENT;

ATOPIC DERMATITIS; COCHRANE LIBRARY; EMBASE; HUMAN; MEDLINE; META ANALYSIS; PLACEBO EFFECT; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PSYCINFO; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; URTICARIA; COMPLICATION; CONTROLLED CLINICAL TRIAL (TOPIC); FEMALE; MALE; PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ANTIPRURITICS; CONTROLLED CLINICAL TRIALS AS TOPIC; DERMATITIS, ATOPIC; FEMALE; HUMANS; MALE; PLACEBO EFFECT; PRURITUS; PSORIASIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; URTICARIA;

EID: 84928432708     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2014.522     Document Type: Review

References (102)

1. Abu Shereeah AM, Youssuf M, Deckers I et al. (1998) Double-blind, parallel, randomized pilot study comparing the efficacy and tolerance of cetiririne 10mg, mequitazine 2-5 mg and placebo in the treatment of patients suffering from chronic urticaria: comparison of suppressive effects on histamine-induced weals and flares. Drug Dev Res 43:185-92
2. Barnett AG, van der Pols JC, Dobson AJ (2005) Regression to the mean: what it is and how to deal with it. Int J Epidemiol 34:215-20
3. Bartels DJ, van Laarhoven AI, Haverkamp EA et al. (2014) Role of conditioning and verbal suggestion in placebo and nocebo effects on itch. PLoS One 9:e91727
4. Benedetti F (2008) Mechanisms of placebo and placebo-related effects across diseases and treatments. Annu Rev Pharmaco Toxicol 48:33-60
5. Bernstein IL, Bernstein DI (1986) Efficacy and safety of astemizole, a longacting and nonsedating H1 antagonist for the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol 77:37-42
6. Berth-Jones J, Graham-Brown RA (1989) Failure of terfenadine in relieving the pruritus of atopic dermatitis. Br J Dermatol 121:635-7
7. Berth-Jones J, Graham-Brown RA (1990) Failure of papaverine to reduce pruritus in atopic dermatitis: a double-blind, placebo-controlled crossover study. Br J Dermatol 122:553-7
8. Berth-Jones J, Takwale A, Tan E et al. (2002) Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br J Dermatol 147:324-30
9. Bissonnette R, Papp K, Poulin Y et al. (2006) A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis. J Am Acad Dermatol 54:472-8
10. Breneman D, Bronsky EA, Bruce S et al. (1995) Cetirizine and astemizole therapy for chronic idiopathic urticaria: a double-blind, placebo-controlled, comparative trial. J Am Acad Dermatol 33:192-8
11. Bressler RB, Sowell K, Huston DP (1989) Therapy of chronic idiopathic urticaria with nifedipine: demonstration of beneficial effect in a double-blinded, placebo-controlled, crossover trial. J Allergy Clin Immunol 83:756-63
12. Brostoff J, Fitzharris P, Dunmore C et al. (1996) Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria. Allergy 51:320-5
13. Bushmakin AG, Mamolo C, Cappelleri JC et al. (2013) The relationship between pruritus and the clinical signs of psoriasis in patients receiving tofacitinib. J Dermatol Treat. advance online publication, 2 December 2013
14. Camarasa JM, Aliaga A, Fernández-Vozmediano JM et al. (2001) Azelastine tablets in the treatment of chronic idiopathic urticaria. Phase iii, randomised, double-blind, placebo and active controlled multicentric clinical trial. Skin Pharmacol Appl Skin Physiol 14:77-86
15. Colloca L, Klinger R, Flor H et al. (2013) Placebo analgesia: psychological and neurobiological mechanisms. Pain 154:511-4
16. Colloca L, Miller FG (2011) How placebo responses are formed: a learning perspective. Philos Trans R Soc Lond B Biol Sci 366:1859-69
17. Di Lorenzo G, Pacor ML, Mansueto P et al. (2004) Randomized placebocontrolled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria. J Allergy Clin Immunol 114:619-25
18. Dubertret L, Murrieta Aguttes M et al. (1999) Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria: results of the MILOR Study. J Eur Acad Dermatol Venereol 12:16-24
19. Dubertret L, Zalupca L, Cristodoulo T et al. (2007) Once-daily rupatadine improves the symptoms of chronic idiopathic urticaria: a randomised, double-blind, placebo-controlled study. Eur J Dermatol 17:223-8
20. Dworkin RH, Turk DC, McDermott MP et al. (2009) Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations. Pain 146:238-44
21. Ebata T, Izumi H, Aizawa H et al. (1998) Effects of nitrazepam on nocturnal scratching in adults with atopic dermatitis: a double-blind placebocontrolled crossover study. Br J Dermatol 138:631-4
22. Eichenfield LF, Tom WL, Berger TG et al. (2014) Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol 71:116-32
23. Feldman SR, Kimball AB, Krueger GG et al. (2005) Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial. J Am Acad Dermatol 53:887-9
24. Ferguson J, MacDonald KJ, Kenicer KJ (1985) Terfenadine and placebo compared in the treatment of chronic idiopathic urticaria: a randomised double-blind study. Br J Clin Pharmacol 20:639-41
25. Finn AF, Kaplan AP, Fretwell R et al. (1999) A double-blind, placebocontrolled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol 104:1071-8
26. Fox RW, Lockey RF, Bukantz SC et al. (1986) The treatment of mild to severe chronic idiopathic urticaria with astemizole: double-blind and open trials. J Allergy Clin Immunol 78:1159-66
27. Friedmann PS, Palmer R, Tan E et al. (2007) A double-blind, placebo-controlled trial of montelukast in adult atopic eczema. Clin Exp Allergy 37:1536-40
28. Frosch PJ, Schwanitz HJ, Macher E (1984) A double blind trial of H1 and H2 receptor antagonists in the treatment of atopic dermatitis. Arch Dermatol Res 276:36-40
29. Gibson JR, Harvey SG, Barth JH (1984) An assessment of the novel antihistamine BW 825C in the treatment of chronic idiopathic urticaria. A placebo-controlled study. Dermatologica 169:179-83
30. Gimenez-Arnau A, Pujol RM, Ianosi S et al. (2007) Rupatadine in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebocontrolled multicentre study. Allergy 62:539-46
31. Goh CL, Wong WK, Lim J (1991) Cetirizine vs placebo in chronic idiopathic urticaria-a double blind randomised cross-over study. Ann Acad Med Singapore 20:328-30
32. Gordon KB, Kimball AB, Chau D et al. (2014) Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: Use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory. Br J Dermatol 170:705-15
33. Gordon KB, Papp KA, Hamilton TK et al. (2003) Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 290:3073-80
34. Guttman-Yassky E, Nograles KE, Krueger JG (2011) Contrasting pathogenesis of atopic dermatitis and psoriasis-part I: clinical and pathologic concepts. J Allergy Clin Immunol 127:1110-8
35. Hauser W, Bartram-Wunn E, Bartram C et al. (2011) Systematic review: Placebo response in drug trials of fibromyalgia syndrome and painful peripheral diabetic neuropathy-magnitude and patient-related predictors. Pain 152:1709-17
36. Hedges LV, Vevea JL (1998) Fixed- and random-effects models in metaanalysis. Psychol Methods 3:486-504
37. Henz BM, Metzenauer P, O'Keefe E et al. (1998) Differential effects of newgeneration H1-receptor antagonists in pruritic dermatoses. Allergy 53:180-3
38. Higgins JPT, Green S (eds) (2009) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2. The Cochrane Collaboration
39. Hosogi M, Schmelz M, Miyachi Y et al. (2006) Bradykinin is a potent pruritogen in atopic dermatitis: a switch from pain to itch. Pain 126:16-23
40. Hrobjartsson A, Gotzsche PC (2004) Is the placebo powerless? Update of a systematic review with 52 new randomized trials comparing placebo with no treatment. J Intern Med 256:91-100
41. Juhlin L, Arendt C (1988) Treatment of chronic urticaria with cetirizine dihydrochloride a non-sedating antihistamine. Br J Dermatol 119:67-71
42. Kailasam V, Mathews KP (1987) Controlled clinical assessment of astemizole in the treatment of chronic idiopathic urticaria and angioedema. J Am Acad Dermatol 16:797-804
43. Kalivas J, Breneman D, Tharp M et al. (1990) Urticaria: clinical efficacy of cetirizine in comparison with hydroxyzine and placebo. J Allergy Clin Immunol 86:1014-8
44. Kaplan A, Ledford D, Ashby M et al. (2013) Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol 132:101-9
45. Kaplan AP, Spector SL, Meeves S et al. (2005) Once-daily fexofenadine treatment for chronic idiopathic urticaria: a multicenter, randomized, double-blind, placebo-controlled study. Ann Allergy Asthma Immunol 94:662-9
46. Kapp A, Pichler WJ (2006) Levocetirizine is an effective treatment in patients suffering from chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, parallel, multicenter study. Int J Dermatol 45:469-74
47. Kavli G, Larsen PO (1981) Double-blind crossover trial comparing systemic chromosome-carboxylic acid with placebo in patients with atopic dermatitis. Allergy 36:597-600
48. Kosnik M, Subic T (2011) Add-on montelukast in antihistamine-resistant chronic idiopathic urticaria. Respir Med 105(Suppl 1):S84-8
49. Krueger GG, Langley RG, Finlay AY et al. (2005) Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol 153:1192-9
50. Leonardi C, Matheson R, Zachariae C et al. (2012) Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 366:1190-9
51. Leung DY, Hirsch RL, Schneider L et al. (1990) Thymopentin therapy reduces the clinical severity of atopic dermatitis. J Allergy Clin Immunol 85:927-33
52. Lintu P, Savolainen J, Kortekangas-Savolainen O et al. (2001) Systemic ketoconazole is an effective treatment of atopic dermatitis with IgEmediated hypersensitivity to yeasts. Allergy 56:512-7
53. Magerl M, Rother M, Bieber T et al. (2013) Randomized, double-blind, placebo-controlled study of safety and efficacy of miltefosine in antihistamine- resistant chronic spontaneous urticaria. J Eur Acad Dermatol Venereol 27:e363-9
54. Malekzad F, Arbabi M, Mohtasham N et al. (2009) Efficacy of oral naltrexone on pruritus in atopic eczema: a double-blind, placebo-controlled study. J Eur Acad Dermatol Venereol 23:948-50
55. Mamolo C, Harness J, Tan H et al. (2013) Tofacitinib (CP-690, 550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 28: 192-203
56. Mamolo CM, Bushmakin AG, Cappelleri JC (2014) Application of the Itch Severity Score in patients with moderate-to-severe plaque psoriasis: clinically important difference and responder analyses. J Dermatol Treat. advance online publication, 10 April 2014
57. Mathias SD, Crosby RD, Zazzali JL et al. (2012) Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol 108:20-4
58. Maurer M, Altrichter S, Bieber T et al. (2011) Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol 128:202-9.e5
59. Maurer M, Magerl M, Metz M et al. (2013a) Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria. J Dtsch Dermatol Ges 11:971-8
60. Maurer M, Rosen K, Hsieh HJ et al. (2013b) Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 368:924-35
61. Meggitt SJ, Gray JC, Reynolds NJ (2006) Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double- blind, randomised controlled trial. Lancet 367:839-46
62. Menter A, Korman NJ, Elmets CA et al. (2009) Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 61:451-85
63. Miller FG, Rosenstein DL (2006) The nature and power of the placebo effect. J Clin Epidemiol 59:331-5
64. Moher D, Liberati A, Tetzlaff J et al. (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097
65. Monroe E, Finn A, Patel P et al. (2003) Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol 48:535-41
66. Monroe EW (1989) Efficacy and safety of nalmefene in patients with severe pruritus caused by chronic urticaria and atopic dermatitis. J Am Acad Dermatol 21:135-6
67. Munro CS, Levell NJ, Shuster S et al. (1994) Maintenance treatment with cyclosporin in atopic eczema. Br J Dermatol 130:376-80
68. Nelson HS, Reynolds R, Mason J (2000) Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria. Ann Allergy Asthma Immunol 84:517-22
69. Oldhoff JM, Darsow U, Werfel T et al. (2005) Anti-IL-5 recombinant humanized monoclonal antibody. Allergy 60:693-6
70. Ortonne JP, Shear N, Shumack S et al. (2005) Impact of efalizumab on patientreported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]. BMC Dermatol 5:13
71. Pacheco-Lopez G, Engler H, Niemi MB et al. (2006) Expectations and associations that heal: immunomodulatory placebo effects and its neurobiology. Brain Behav Immun 20:430-46
72. Pacor ML, Lorenzo G, Corrocher R (2001) Efficacy of leukotriene receptor antagonist in chronic urticaria. A double-blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic acid. Clin Exp Allergy 31:1607-14
73. Papoiu AD, Wang H, Coghill RC et al. (2011) Contagious itch in humans. A study of visual "transmission" of itch in atopic dermatitis and healthy subjects. Br J Dermatol 164:1299-303
74. Papp K, Cather JC, Rosoph L et al. (2012) Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet 380:738-46
75. Peremans W, Mertens RL, Morias J et al. (1981) Oxatomide in the treatment of chronic urticaria. A double-blind placebo-controlled trial. Dermatologica 162:42-50
76. Pittler MH, Armstrong NC, Cox A et al. (2003) Randomized, double-blind, placebo-controlled trial of autologous blood therapy for atopic dermatitis. Br J Dermatol 148:307-13
77. Pollo A, Carlino E, Benedetti F (2011) Placebo mechanisms across different conditions: from the clinical setting to physical performance. Philos Trans R Soc London Ser B Biol Sci 366:1790-8
78. Revicki D, Willian MK, Saurat JH et al. (2008) Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol 158:549-57
79. Revicki DA, Willian MK, Menter A et al. (2007) Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatol Treat 18:341-50
80. Rief W, Bingel U, Schedlowski M et al. (2011) Mechanisms involved in placebo and nocebo responses and implications for drug trials. Clin Pharmacol Ther 90:722-6
81. Ring J, Hein R, Gauger A et al. (2001) Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol 40:72-6
82. Saini S, Rosen KE, Hsieh HJ et al. (2011) A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1- antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol 128:567-73.e1
83. Saini SS (2014) Chronic spontaneous urticaria: etiology and pathogenesis. Immun Allergy Clin North Am 34:33-52
84. Schneider G, Driesch G, Heuft G et al. (2006) Psychosomatic cofactors and psychiatric comorbidity in patients with chronic itch. Clin Exp Dermatol 31:762-7
85. Shupack J, Stiller M, Meola T et al. (1991) Papaverine hydrochloride in the treatment of atopic dermatitis: a double-blind, placebo-controlled crossover clinical trial to reassess safety and efficacy. Dermatologica 183:21-4
86. Sidbury R, Davis DM, Cohen DE et al. (2014) Guidelines of care for the management of atopic dermatitis: Section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol 71:327-49
87. Sowden JM, Berth-Jones J, Ross JS et al. (1991) Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet 338:137-40
88. Ständer S, Schafer I, Phan NQ et al. (2010) Prevalence of chronic pruritus in Germany: results of a cross-sectional study in a sample working population of 11 730. Dermatology 221:229-35
89. Stiller MJ, Shupack JL, Kenny C et al. (1994) A double-blind, placebocontrolled clinical trial to evaluate the safety and efficacy of thymopentin as an adjunctive treatment in atopic dermatitis. J Am Acad Dermatol 30:597-602
90. Tyring S, Gottlieb A, Papp K et al. (2006) Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 367:29-35
91. Van Joost T, Heule F, Korstanje M et al. (1994) Cyclosporin in atopic dermatitis: a multicentre placebo-controlled study. Br J Dermatol 130:634-40
92. Van Laarhoven AI, Vogelaar ML, Wilder-Smith OH et al. (2011) Induction of nocebo and placebo effects on itch and pain by verbal suggestions. Pain 152:1486-94
93. Vase L, Petersen GL, Riley JL III et al. (2009) Factors contributing to large analgesic effects in placebo mechanism studies conducted between 2002 and 2007. Pain 145:36-44
94. Vase L, Riley JL III, Price DD (2002) A comparison of placebo effects in clinical analgesic trials versus studies of placebo analgesia. Pain 99: 443-52
95. Verhoeven EW, Kraaimaat FW, van de Kerkhof PC et al. (2007) Prevalence of physical symptoms of itch, pain and fatigue in patients with skin diseases in general practice. Br J Dermatol 156:1346-9
96. Wahlgren CF, Hägermark O, Bergström R (1990a) The antipruritic effect of a sedative and a non-sedative antihistamine in atopic dermatitis. Br J Dermatol 122:545-51
97. Wahlgren CF, Scheynius A, Hägermark O (1990b) Antipruritic effect of oral cyclosporin A in atopic dermatitis. Acta Derm Venereol 70:323-9
98. Wan KS (2009) Efficacy of leukotriene receptor antagonist with an anti-H1 receptor antagonist for treatment of chronic idiopathic urticaria. J Dermatol Treat 20:194-7
99. Weisshaar E, Dalgard F (2009) Epidemiology of itch: adding to the burden of skin morbidity. Acta Derm Venereol 89:339-50
100. Wolff K, Fleming C, Hanifin J et al. (2005) Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial. Br J Dermatol 152:1296-303
101. Zhang W, Robertson J, Jones AC et al. (2008) The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials. Ann Rheum Dis 67:1716-23
102. Zuberbier T, Oanta A, Bogacka E et al. (2010) Comparison of the efficacy and safety of bilastine 20mg vs levocetirizine 5mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy 65:516-28